Ra Pharmctl (NASDAQ: RARX) has recently received a number of price target changes and ratings updates:

  • 9/19/2017 – Ra Pharmctl was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Ra Pharmaceuticals, Inc. is a biopharmaceutical company. It involved in the discovery and development of novel therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. Ra Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. “
  • 9/14/2017 – Ra Pharmctl is now covered by analysts at Royal Bank Of Canada. They set an “outperform” rating and a $21.00 price target on the stock.
  • 9/5/2017 – Ra Pharmctl was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Ra Pharmaceuticals, Inc. is a biopharmaceutical company. It involved in the discovery and development of novel therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. Ra Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. “
  • 8/29/2017 – Ra Pharmctl was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Ra Pharmaceuticals, Inc. is a biopharmaceutical company. It involved in the discovery and development of novel therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. Ra Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. “
  • 8/25/2017 – Ra Pharmctl was given a new $25.00 price target on by analysts at Jefferies Group LLC. They now have a “buy” rating on the stock.
  • 8/22/2017 – Ra Pharmctl was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Ra Pharmaceuticals, Inc. is a biopharmaceutical company. It involved in the discovery and development of novel therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. Ra Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. “

Ra Pharmctl Inc (RARX) opened at 15.44 on Tuesday. The company has a 50-day moving average of $14.64 and a 200 day moving average of $15.47. Ra Pharmctl Inc has a one year low of $12.05 and a one year high of $24.12. The firm’s market cap is $349.08 million.

Ra Pharmctl (NASDAQ:RARX) last issued its quarterly earnings data on Wednesday, August 9th. The company reported ($0.56) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.50) by ($0.06). Equities research analysts expect that Ra Pharmctl Inc will post ($2.31) earnings per share for the current fiscal year.

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

Receive News & Stock Ratings for Ra Pharmctl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmctl Inc and related stocks with our FREE daily email newsletter.